Rise Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Rise Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-187	Closed	-$623	–	1599
2025 Q1	$623	Buy	+187	New	+$964	﹤0.01%	1348

Other funds holding IOVA

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rise Advisors's IOVA Position: Q2 2025 in Review

Rise Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 187 shares — an estimated $623 sold.

Rise Advisors first reported a position in IOVA in Q1 2025 and held it in 1 quarter. The position peaked at $623 in Q1 2025. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

Rise Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 187 Iovance Biotherapeutics shares in Q2 2025, an estimated $623.
Rise Advisors first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 1 quarter.
Rise Advisors's Iovance Biotherapeutics position peaked at $623 in Q1 2025.
255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.